Company intelligence / Profile preview

EyGen

Ownership: Private
Development stage: Other

Overview

EyGen is a Canadian biotech company spun out from Portage Biotech in 2016. Its lead asset, PPL-003, is an NF-κB inhibitor being developed for dry eye syndromes. As of early 2025, the program has not yet entered clinical trials ("Pending" status), and there are no reported clinical results or approvals.[2][3]

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

PPL-003

Preclinical

Beyond the preview

Go deeper on EyGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyGen.

Explore the full profile